Abstract
Background In addition to age and sex, also smoking history and levels of blood pressure, cholesterol, lipoproteins and inflammation are established biomarkers for coronary heart disease (CHD). As standard polygenic risk scores (PRS) have recently proven successful for CHD prediction, it remains of high interest to determine how a combined PRS of biomarkers (BioPRS) constructed from statistically relevant biomarkers can further improve genetic prediction of CHD.
Methods We developed CHDBioPRS, which combines BioPRS with PRS of CHD, via regularized regression in UK Biobank (UKB) training data (n = 208,010). The resulting CHDBioPRS was tested on an independent UK Biobank subset (n = 25,765) and on the FinnGen study (n = 306,287).
Results We observed a consistent pattern across all data sets where BioPRS was clearly predictive of CHD and improved standard PRS for CHD when the two were combined. In UKB test data, CHDPRS had a hazard ratio (HR) of 1.78 (95% confidence interval 1.67-1.91, area under the curve (AUC) 0.808) and CHDBioPRS had a HR of 1.88 (1.75-2.01, AUC 0.811) per one standard deviation of PRS. In FinnGen data, HR of CHDPRS was 1.57 (1.55-1.60, AUC 0.752) and HR of CHDBioPRS was 1.60 (1.58-1.62, AUC 0.755). We observed larger effects of CHDBioPRS in subsets of early onset cases with HR of 2.07 (1.85-2.32, AUC 0.790) in UKB test data and of 2.10 (2.04-2.16, AUC 0.791) in FinnGen. Results were similar when stratified by sex.
Conclusions Integration of biomarker based BioPRS improved on the standard PRS for CHD and the gain was largest with early onset CHD cases. These findings highlight the benefit of enriching polygenic risk prediction of CHD with the genetics of associated biomarkers.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Academy of Finland (grant nos. 325999 for JL, 331671 for NM, 312076 and 336825 for MP, 285380 and 312062 for SR), by Sigrid Juselius Foundation (MP and SR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The FinnGen study is approved by Finnish Institute for Health and welfare (permit numbers: THL/2031/6.02.00/2017, THL/1101/5.05.00/2017, THL/341/6.02.00/2018, THL/2222/6.02.00/2018, THL/283/6.02.00/2019, THL/1721/5.05.00/2019, THL/1524/5.05.00/2020, and THL/2364/14.02/2020), Digital and population data service agency (permit numbers: VRK43431/2017-3, VRK/6909/2018-3, VRK/4415/2019-3), the Social Insurance Institution (permit numbers: KELA 58/522/2017, KELA 131/522/2018, KELA 70/522/2019, KELA 98/522/2019, KELA 138/522/2019, KELA 2/522/2020, KELA 16/522/2020, Findata THL/2364/14.02/2020 and Statistics Finland (permit numbers: TK-53-1041-17 and TK/143/07.03.00/2020 (earlier TK-53-90-20). The Biobank Access Decisions for FinnGen samples and data utilized in FinnGen Data Freeze 7 include: THL Biobank BB2017_55, BB2017_111, BB2018_19, BB_2018_34, BB_2018_67, BB2018_71, BB2019_7, BB2019_8, BB2019_26, BB2020_1, Finnish Red Cross Blood Service Biobank 7.12.2017, Helsinki Biobank HUS/359/2017, Auria Biobank AB17-5154 and amendment #1 (August 17 2020), Biobank Borealis of Northern Finland_2017_1013, Biobank of Eastern Finland 1186/2018 and amendment 22/2020, Finnish Clinical Biobank Tampere MH0004 and amendments (21.02.2020 & 06.10.2020), Central Finland Biobank 1-2017, and Terveystalo Biobank STB 2018001. Approval for this research also has been conducted using the UK Biobank Resource under Application Number 22627.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors. Upon acceptance, all relevant data will be submitted to the Polygenic Score Catalog.
